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Abstract 
Background: Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combi-
nation chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in 
patients with progression or recurrence after platinum-based chemotherapy. Preclinical and clinical evidence sug-
gests that radiotherapy has a systemic anti-cancer immune effect and can increase the level of PD-L1 and tumor infil-
trating lymphocytes in the tumor microenvironment. These findings gave rise to the hypothesis that the combination 
of radiotherapy with anti-PD1 treatment could lead to a synergistic effect, hereby enhancing response rates.
Methods: The phase I part will assess the dose limiting toxicity of the combination treatment of stereotactic body 
radiotherapy (SBRT) with four cycles of pembrolizumab (200 mg intravenously, every 3 weeks) in patients with meta-
static urothelial carcinoma. The dose of both pembrolizumab and SBRT will be fixed, yet the patients will be rand-
omized to receive SBRT either before the first cycle of pembrolizumab or before the third cycle of pembrolizumab. 
SBRT will be delivered (24 Gy in 3 fractions every other day) to the largest metastatic lesion. Secondary objectives 
include response rate according to RECIST v1.1 and immune related response criteria, progression-free survival and 
overall survival. The systemic immune effect triggered by the combination therapy will be monitored on various time 
points during the trial. The PD-L1/TIL status of the tumors will be analyzed via immunohistochemistry and response 
rates in the subgroups will be analyzed separately. A Simon’s two-stage optimum design is used to select the treat-
ment arm associated with the best response rate and with acceptable toxicity to proceed to the phase II trial. In this 
phase, 13 additional patients will be accrued to receive study treatment.
Discussion: The progress made in the field of immunotherapy has lead to promising breakthroughs in various solid 
malignancies. Unfortunately, the majority of patients do not respond. The current trial will shed light on the toxic-
ity and potential anti-tumor activity of the combination of radiotherapy with anti-PD1 treatment and may identify 
potential new markers for response and resistance to therapy. Trial registration this trial is registered on clinicaltrials.
gov (NCT02826564).
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Background
Metastatic urothelial carcinoma remains a disease that 
is associated with few therapeutic options, poor prog-
nosis and short-term survival. Worldwide, an estimated 
429,800 of new cases of urinary bladder cancer and 
165,100 deaths occurred in 2012 [1].
Cisplatin-containing combination therapy is standard-
of-care for metastatic patients, with a median overall 
survival (OS) of 12.5–15 months and a long-term disease 
free survival in about 15% of patients [2–5]. Unfortu-
nately, approximately 50% of patients are unfit for cispl-
atin-containing chemotherapy and may only be palliated 
with carboplatin-based regimens, without a statistically 
significant improvement in OS or progression-free sur-
vival (PFS) [2, 6].
Therapies blocking the PD-1/PD-L1 pathway (e.g. 
pembrolizumab, nivolumab and atezolizumab) have 
shown encouraging responses in patients with meta-
static urothelial carcinoma, with an overall response rate 
of 15–26% [6–10]. This has resulted in the recent FDA 
approval of nivolumab and atezolizumab for the treat-
ment of patients with locally advanced or metastatic 
urothelial carcinoma whose disease has worsened dur-
ing or following platinum-containing chemotherapy, 
or within 12  months of receiving platinum-containing 
chemotherapy, either before (neoadjuvant) or after (adju-
vant) surgical treatment. Patients responding to anti-
PD-1/PD-L1 therapy often have tumors with elevated 
PD-1 and PD-L1 expression and are infiltrated by CD8+ 
cytotoxic tumor infiltrating lymphocytes (TIL) [8, 9, 11, 
12]. These tumors are referred to as PD-L1+ TIL+.
Unfortunately, a substantial number of patients do 
not respond to anti-PD-1/PD-L1 therapy, often patients 
with low levels of tumor-infiltrating CD8+ T cells and 
no signs of T cell activation [12, 13]. These tumors are 
referred to as PD-L1− TIL−. It is hypothesized that in 
these non-responding patients, the tumor microenviron-
ment might hinder T cell infiltration and induction of 
local endogenous immune responses.
Radiotherapy might increase response rates by creat-
ing a more permissive tumor microenvironment through 
increasing PD-L1 expression on tumor cells [14] and stim-
ulating the accumulation and activation of CD8+ T cells 
[15], all markers for response. Preclinical evidence clearly 
indicates that combining radiotherapy with anti-PD-1 
treatment increases the anti-tumoral activity of both treat-
ments and even produces long-term survival [16]. On the 
one hand, radiotherapy might stimulate the induction of 
local endogenous immune responses by anti-PD-1 treat-
ment. On the other hand, active immune stimulation by 
anti-PD-1 treatment within the tumor microenvironment 
might maximize radiation-induced antitumor immu-
nity. These positive effects of radiotherapy are most often 
observed using high-dose per fraction radiotherapy (>5 Gy 
per fraction), which can be delivered safely in patients 
using stereotactic body radiotherapy (SBRT) [17–19].
Both anti-PD-1 treatment as well as SBRT (3 × 8 Gy) have 
shown to be safe when applied separately with grade 3–5 
treatment related adverse events in 15% [10] and 11,7% [20] 
of patients respectively. Before the combination of drugs 
can be implemented in routine practice, the safety has to 
be established in a phase I trial as SBRT might increase the 
toxicity of anti-PD-1 treatment or the other way around. In 
addition, the timing of SBRT might influence the induction 
of antitumor immunity; yet this has not been thoroughly 
investigated [21]. Consequently, patients will be randomized 
into two arms with different timing of SBRT.
This trial uses a parallel phase I/II clinical trial design 
for combination therapies [22]. This design allows assess-
ment of the safety and the efficacy of a combination 
therapy (pembrolizumab and SBRT) in a relatively small 
number of patients [22].
Methods/design
Objectives
The primary objective of the phase I trial is to evaluate 
the safety of the combination treatment and determine 
the SBRT-schedule associated with dose limiting toxicity 
(DLT) in <20% of patients.
The secondary objectives of the phase I trial are to 
assess the response rate according to the response evalu-
ation criteria (RECIST) v1.1 and the  immune related 
response criteria (irRC), local control, progression-free 
survival and overall survival. Exploratory endpoints 
include systemic immunologic responses and response 
rates in PD-L1− TIL− tumors.
Trial design
This trial uses a parallel phase I/II clinical trial design for 
combination therapies [22]. Pembrolizumab (200  mg, 
intravenously) will be administered every 3  weeks until 
disease progression or unacceptable toxicity. Patients will 
be randomized to receive SBRT either before the first cycle 
of pembrolizumab or before the third cycle of pembroli-
zumab. SBRT will be delivered (24 Gy in 3 fractions every 
other day) to the largest metastatic lesion that can be irra-
diated safely; the last fraction will be administered 1  day 
prior to the subsequent cycle of pembrolizumab. Figure 1 
shows a general scheme of the trial design. A more detailed 
table of the trial enrolment, interventions and assessments 
can be found in the Additional file 1: Table S1.
Outcome measures
Primary endpoint
  • DLT occurring between the start of SBRT and 
12  weeks after completion of SBRT. DLT will be 
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assessed using the Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0. DLT should 
be, completely or in part, related to trial therapy. The 
following events will be considered as DLT: 
• any grade 3–5 metabolic or hematological toxicity 
that is related, probably related or possibly related 
to pembrolizumab or SBRT.
•  any grade 3–5 non-hematological toxicity that is 
related, probably related or possibly related to SBRT.
Secondary endpoints
  • Objective response rate in the non-irradiated metasta-
ses as determined by RECIST v1.1 [23]. Response rate 
will be defined as the percentage of subjects achiev-
ing either a complete or a partial response at 12 weeks 
after the start of pembrolizumab. During treatment all 
patients will undergo a CT of the chest, abdomen and 
pelvis every 9 weeks or sooner if clinically indicated.
  • Objective response rate in the non-irradiated metas-
tases as determined by irRC [24] at 12 weeks after the 
start of pembrolizumab.
  • Local control defined as the time between local irra-
diation and the moment the irradiated lesion shows 
an increase in size of ≥20%, according to the RECIST 
v1.1, confirmed by a consecutive assessment at least 
4 weeks after first documentation.
  • PFS defined as the time from inclusion to docu-
mented disease progression according to irRC or 
death from any cause.
  • OS defined as the time from inclusion to death from 
any cause.
Exploratory endpoints
  • Response rate according to expression of PD-L1. 
PD-L1 expression will be determined by immuno-
histochemistry in QualTek Molecular Laboratories 
on an archival or newly obtained tissue sample of the 
tumor or metastatic lesion.
  • Immunologic response in peripheral blood sam-
ples analyzed via fluorescence-activated cell sorting 
(FACS) phenotyping, ultra-performance liquid chro-
matography (UPLC) and enzyme-linked immune-
sorbent assay (ELISA).
Fig. 1 General scheme of the trial design
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Study population
Inclusion criteria
  • Be willing and able to provide written informed con-
sent/assent for the trial.
  • Be ≥18 years of age on day of signing informed con-
sent.
  • Have at least two measurable lesions according to 
RECIST v1.1.
  • Have had any prior treatment more than 2  weeks 
prior to study day 1, treatment naïve patients are 
allowed.
  • Histological confirmed diagnosis of urothelial carci-
noma.
  • Be willing to provide tissue from a newly obtained 
core or excisional biopsy of a tumor lesion. Newly-
obtained is defined as a specimen obtained up to 
6 weeks (42 days) prior to initiation of treatment on 
day 1. Subjects for whom newly-obtained samples 
cannot be provided (e.g. inaccessible or subject safety 
concern) may submit an archived specimen only upon 
agreement from the sponsor.
  • Have a performance status of 0 or 1 on the ECOG 
performance scale.
  • Demonstrate adequate organ function as defined 
in Table  1, all screening labs should be performed 
within 10 days before treatment initiation.
  • Female subjects of childbearing potential should have 
a negative urine or serum pregnancy within 72  h 
prior to receiving the first dose of study medication. 
If the urine test is positive or cannot be confirmed as 
negative, a serum pregnancy test will be required.
  • Female subjects of childbearing potential must be 
willing to use an adequate method of contraception 
for the course of the study through 120  days after 
the last dose of study medication. Note: Abstinence 
is acceptable if this is the usual lifestyle and preferred 
contraception for the subject.
  • Male subjects of childbearing potential must agree 
to use an adequate method of contraception starting 
with the first dose of study therapy through 120 days 
after the last dose of study therapy. Note: Abstinence 
is acceptable if this is the usual lifestyle and preferred 
contraception for the subject.
  • The subject is currently not participating or receiving 
study therapy and has not participated in a study of 
an investigational agent and received study therapy 
or used an investigational device within 4  weeks of 
the first dose of treatment.
  • No prior radiotherapy interfering with SBRT.
  • No diagnosis of immunodeficiency and no systemic 
steroid therapy or any other form of immunosup-
pressive therapy within 7 days prior to the first dose 
of trial treatment.
  • No history of active tuberculosis.
  • No hypersensitivity to pembrolizumab or any of its 
excipients.
  • Has not received any prior anti-cancer monoclo-
nal antibody within 4 weeks prior to study day 1 or 
has not recovered (i.e. ≥grade 1 or at baseline) from 
adverse events due to agents administered more than 
4 weeks earlier.
  • No prior chemotherapy, targeted small molecule 
therapy, or radiation therapy within 2 weeks prior to 
study day 1 or no recovering (i.e. ≤grade 1 or at base-
line) from adverse events due to a previously admin-
istered agent.
a. Note: Subjects with ≤grade 2 neuropathy are an 
exception to this criterion and may qualify for 
the study.
b. Note: If subject received major surgery, they 
must have recovered adequately from the toxic-
ity and/or complications from the intervention 
prior to starting therapy.
  • No additional malignancy that is progressing or 
requires active treatment. Exceptions include basal 
cell carcinoma of the skin or squamous cell carci-
Table 1 Adequate organ function laboratory values
a Creatinine clearance should be calculated per institutional standard
System Laboratory value
Hematological
 Absolute neutrophil count ≥1500/mcL
 Platelets ≥100,000/mcL
 Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without trans-
fusion or EPO dependency (within 
7 days of assessment)
Renal
 Serum creatinine OR
Measured or  calculateda 
creatinine clearance
≤1.5 X upper limit of normal (ULN) OR
≥60 mL/min for subject with creatinine 
levels >1.5 X institutional ULN
Hepatic
 Serum total bilirubin ≤1.5 X ULN OR
Direct bilirubin ≤ULN for subjects with 
total bilirubin levels >1.5 ULN
 AST (SGOT) and ALT (SGPT) ≤2.5 X ULN OR
≤5 X ULN for subjects with liver metas-
tases
 Albumin ≥25 g/L
Coagulation
 International normalized 
ratio (INR) or prothrombin 
time (PT)
Activated partial thrombo-
plastin time (aPTT)
≤1.5 X ULN unless subject is receiving 
anticoagulant therapy as long as PT 
or PTT is within therapeutic range of 
intended use of anticoagulants
≤1.5 X ULN unless subject is receiving 
anticoagulant therapy as long as PT 
or PTT is within therapeutic range of 
intended use of anticoagulants
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noma of the skin that has undergone potentially 
curative therapy or in situ cervical cancer.
  • No active central nervous system metastases and/or 
carcinomatous meningitis. Subjects with previously 
treated brain metastases may participate provided 
they are stable (without evidence of progression by 
imaging for at least 4 weeks prior to the first dose of 
trial treatment and any neurologic symptoms have 
returned to baseline), have no evidence of new or 
enlarging brain metastases, and are not using ster-
oids for at least 7 days prior to trial treatment. This 
exception does not include carcinomatous meningitis 
which is excluded regardless of clinical stability.
  • No active autoimmune disease that has required sys-
temic treatment in the past 2  years (i.e. with use of 
disease modifying agents, corticosteroids or immu-
nosuppressive drugs). Replacement therapy (e.g. thy-
roxine, insulin, or physiologic corticosteroid replace-
ment therapy for adrenal or pituitary insufficiency, 
etc.) is not considered a form of systemic treatment.
  • No known history of, or any evidence of active, non-
infectious pneumonitis.
  • No active infection requiring systemic therapy.
  • No history or current evidence of any condition, 
therapy, or laboratory abnormality that might con-
found the results of the trial, interfere with the sub-
ject’s participation for the full duration of the trial, or 
is not in the best interest of the subject to participate, 
in the opinion of the treating investigator.
  • No known psychiatric or substance abuse disor-
ders that would interfere with cooperation with the 
requirements of the trial.
  • Is not pregnant or breastfeeding, or expecting to con-
ceive or father children within the projected duration 
of the trial, starting with the pre-screening or screen-
ing visit through 120 days after the last dose of trial 
treatment.
  • Has not received prior therapy with an anti-PD-1, 
anti-PD-L1, or anti-PD-L2 agent.
  • No known history of human immunodeficiency 
virus.
  • No known active hepatitis B or hepatitis C.
  • Subjects should not have received a live vaccine 
within 30 days of planned start of study therapy.
Enrolment, randomization and evaluation
Patients must be restaged within 4  weeks prior to ran-
domization with CT scans of the chest, abdomen and 
small pelvis. Patients will be enrolled by NS; they will 
then be randomly allocated to treatment arm A or B. 
The allocation sequence will be generated by EG and DR. 
Randomization will find place according to the time-to-
event continual reassessment method (TITE-CRM) [25] 
with a variable length block design. This entails that prior 
to randomization of the next block of patients, the pos-
terior probability of the toxicity at that time point will be 
determined. If the chance that the posterior probability 
exceeds 0.2 is more than 0.7, the treatment arm will be 
closed. No blinding will find place.
Intervention
SBRT
A total dose of 24  Gy will be delivered to one lesion in 
3 fractions with image-guided treatment verification and 
fractions will be separated >48 and <96 h.
All patients will receive a CT in supine position with 
3  mm CT slice thickness through the tumor site. The 
planning simulation should cover the target and all 
organs at risk. A typical scan length should extend at 
least 10  cm superior and inferior beyond the treatment 
field borders. Support devices to increase patient comfort 
will be chosen depending on the tumor localization. Lung 
and liver tumor sites will be simulated with 4D-CT, tak-
ing into account breathing. The isocenter will be deter-
mined on the CT-simulator with marking of laser lines 
on the patient. Imaging data will be transferred to the 
treatment planning system. For all lesions, the gross tar-
get volume (GTV) will be defined as all visible tumor by 
combining iconographic and metabolic information. No 
additional margin will be added for microscopic spread 
of disease. The GTV will be expanded with 2–5  mm to 
the planning target volume (PTV) to account for organ 
motion and setup error. Margins depend on the site irra-
diated, with 2 mm margins for bony lesions and 5 mm for 
other sites. The type of organ at risk delineated depends 
on the localization of the metastasis. A planning organ 
at risk volume (PRV) expansion of 2  mm will be added 
for organs at risk (OAR) and dose constraints apply to 
this PRV. It is strongly recommended that dose con-
straints not be exceeded. If a dose constraint cannot be 
achieved due to overlap of the target with an organ at 
risk or its PRV, the fractionation can be increased or the 
target coverage compromised in order to meet the con-
straint. Treatment will be prescribed to the periphery of 
the target (80% of the dose) covering the 90% of the PTV. 
Dose constraints of organs at risk will be in accordance 
with the recommendations of the American Association 
of Physicist in Medicine (AAPM) task group 101 report 
[26].
Pembrolizumab
Pembrolizumab will be administered intravenously at a 
fixed dose of 200  mg per cycle. Pembrolizumab will be 
continued for up to 2 years until clinical progression or 
unacceptable toxicity. Pembrolizumab will be continued 
in clinically stable patients with initial evidence of disease 
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progression. For suspected immune-related adverse reac-
tions, adequate evaluation to confirm etiology or exclude 
other causes should be ensured. Based on the severity of 
the adverse reaction, pembrolizumab should be withheld 
and corticosteroids administered. Upon improvement 
to grade ≤1, corticosteroid taper should be initiated 
and continued over at least 1  month. Pembrolizumab 
may be restarted within 12 weeks after last dose of pem-
brolizumab if the adverse reaction remains at grade ≤1 
and corticosteroid dose has been reduced to ≤10  mg 
prednisone or equivalent per day. Pembrolizumab must 
be permanently discontinued for any grade 3 immune 
related adverse reaction that recurs and for any grade 
4 immune related adverse reaction toxicity, except for 
endocrinopathies that are controlled with replacement 
hormones. The subject may also discontinue protocol 
in case of intercurrent illness which would in the judg-
ment of the investigator affect patient safety, the ability to 
deliver treatment or by request of the patient.
Subjects who stop pembrolizumab with stable disease 
or better may be eligible for up to 1  year of additional 
pembrolizumab therapy if they progress after stopping 
study treatment (only if the study remains open and the 
subject meets certain criteria).
Evaluation of the immunological response
The study requires blood samples (ethylenediaminetet-
raacetic acid (EDTA) and serum) before start of anti-PD-1 
treatment, before start of SBRT, 7 days after end of radio-
therapy and at the time of evaluation. The samples will be 
analysed with FACS phenotyping, UPLC and ELISA. The 
immune response will be analysed with a comprehensive 
immunophenotyping on peripheral blood, looking at abso-
lute lymphocyte count, absolute neutrophil count/absolute 
lymphocyte count, serum tryptophan and kynurenine, 
C-reactive protein and cytokines, serum vascular endothe-
lial growth factor levels, frequencies of Foxp3+ regula-
tory T cells, indoleamine 2, 3-dioxygenase+ plasmacytoid 
dendritic cells and myeloid derived suppressor cells, next 
to functional analysis looking at shifts in Th1/Th2/Th17 
polarization as a function of treatment [27, 28].
Concomitant care
In general, medications or vaccinations specifically pro-
hibited in the exclusion criteria are not allowed dur-
ing the ongoing trial. Systemic glucocorticoids may be 
administered to modulate symptoms from an event of 
suspected immunologic etiology. All treatments that the 
investigator considers necessary for a subject’s welfare 
may be administered at the discretion of the investiga-
tor in keeping with the community standards of medical 
care. Adverse events will be managed according to most 
recent available guidelines.
Follow‑up
Patients will be seen before the start of each treatment 
cycle during the whole course of pembrolizumab therapy. 
At each visit, a history, directed physical examination 
and a routine laboratory blood analysis will be con-
ducted with recording of the toxicity. Tumors will be re-
evaluated every 9 weeks. A safety follow-up visit will find 
place approximately 30  days after the last dose of trial 
treatment or before the initiation of a new anti-cancer 
treatment, whichever comes first. Once a subject expe-
riences confirmed disease progression or starts a new 
anti-cancer therapy, the subject moves into the survival 
follow-up phase and should be contacted by telephone 
every 12  weeks to assess for survival status until death, 
withdrawal of consent, or the end of the study, whichever 
occurs first. Subjects who discontinue trial treatment for 
a reason other than disease progression will move into 
the follow-up phase and will be assessed every 12 weeks 
by radiologic imaging to monitor disease status.
Sample size
In the first phase of the trial 20 patients will be recruited 
and randomly assigned to a treatment arm. If the chance 
that the posterior toxicity probability rate exceeds 0.2 is 
more than 0.7 in a certain arm, this arm will be closed.
The secondary endpoint is the assessment of the 
response rate of the combination treatment in non-
irradiated metastases in every arm. For this analysis a 
Simon’s two-stage optimum design will be used [29]. 
The arm with the best response rate and with accept-
able toxicity will be used to proceed into the second 
phase. The null hypothesis that the true response rate 
is 0.21 [10] will be tested against a one-sided alterna-
tive. If there are two or fewer responses, the alternative 
hypothesis will be rejected. Otherwise 13 additional 
patients will be accrued for a phase II trial. The null 
hypothesis will be rejected if 7 or more responses are 
observed in 23 patients. This design yields a type I error 
rate of 0.15 and power of 0.8 when the true response 
rate is 0.41 (Table 2). We consider the chance that both 
arms in phase 1 are deemed safe with equal toxicity and 
equal response rates very small. Since both arms will 
then qualify to continue to phase 2, selection of one arm 
will depend on secondary outcomes available at that 
time (e.g. PFS, OS).
Data analysis
  • The current trial aims to evaluate the safety of the 
combination treatment of pembrolizumab with SBRT 
and determine whether the sequence of these thera-
pies matters. The primary endpoint is DLT assessed 
using CTCAE version 4.0. The SBRT schedule associ-
ated with DLT in <20% of patients will be determined 
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based on the incidence of treatment-related adverse 
events.
  • Response rates will be determined using RECIST 
v1.1. The null hypothesis that the true response rate 
is 0.21 [10] will be tested against a one-sided alterna-
tive. The null hypothesis will be rejected if seven or 
more responses are observed in 23 patients.
  • Survival times are defined from the day of randomi-
zation until progression, last follow-up or death. 
Cases will be censored at last follow up visit if no pro-
gression was observed. Multivariate analysis will be 
performed according to the cox-regression method.
  • For the evaluation of immunological markers, 
median values between two groups will be compared 
by the Mann–Whitney U test, between >2 groups 
with Kruskal–Wallis testing. To compare propor-
tions of categorical variables, the Pearson’s  Chi2 test 
or Fisher’s Exact test will be used. To evaluate cor-
relations, Spearman correlation coefficients will be 
calculated. All statistical analyses will be performed 
using SPSS 24.0 (SPSS Inc, Chicago, IL, USA), a P 
value <0.05 will be considered statistically significant.
  • When missing data occurs, analysis will find place 
with the available data. Due to the small sample size, 
no imputing will find place.
Study approval and recruitment
This trial is approved by the Ethics committee of the 
Ghent University Hospital (EC2016/0661) and is regis-
tered on clinicaltrials.gov (NCT02826564).
Patient recruitment finds place at the Ghent University 
Hospital, Belgium. The first participant was enrolled on 
November 14th 2016. Participants are currently being 
recruited and enrolled.
Protocol version 3.0; 12th of April, 2017.
Monitoring
  • Safety analysis will find place when all participants 
have passed 12  weeks after administration of SBRT. 
Immediately before allocation of a new participant, 
the posterior toxicity probability will be calculated by 
the statisticians in order to evaluate whether an arm 
should be terminated. Unless an arm is closed, only 
the statisticians will have access to the data regarding 
posterior toxicity probability.
  • The trial conduct is monitored at least once annually 
by Bimetra Clinical Research Center Ghent and by 
MSD Belgium. This is independent from the investi-
gators and the sponsor.
Discussion
Immunotherapy has lead to breakthroughs in vari-
ous solid tumors and can induce spectacular clinical 
responses. Yet unfortunately, responses are still only seen 
in the minority of patients. Several pre-clinical and clini-
cal evidence indicate that radiotherapy instigates a sys-
temic anti-cancer immune effect. One of these immune 
effects is the upregulation of PD-L1 expression and the 
presence of TILs in the tumor microenvironment. There-
fore, the hypothesis was formed that the combination 
of anti-PD1 treatment with radiotherapy could work 
synergistically and raise response rates in patients with 
metastatic urothelial carcinoma. The current phase I/
II trial will, firstly, investigate the safety of two different 
sequences of this combination treatment. In a second 
phase, the response rates of the combination treatment 
will be assessed. Throughout the study, the systemic 
immune effect of both treatments will be monitored on 
different time points. This information can aid in the fine 
tuning of combination therapies and may identify predic-
tors of response or resistance to therapy or even pinpoint 
new potential targets for immunotherapy.
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